Freenome, Inc.
FRNMHealthcareNASDAQDiagnostics & Research · Last scanned Sep 9, 2026
Scan Results
Daily timeframeFreenome, Inc. operates as a biotechnology company in the United States. Valued at $1.72B, FRNM is a small-cap name in its sector. The company offers an early cancer detection platform that integrates multiomics, artificial intelligence, and machine learning to uncover complex biological signals associated with cancer.
Market Cap
$1.72B
Beta
0.48
P/E (TTM)
—
P/E (Fwd)
-6.66
EPS (TTM)
$-2.07
EPS (Fwd)
$-2.40
ROE
—
ROA
—
Cash
$102.0M
Total Debt
$311.5M
Free CF
—
52W Change
54.6%
Annual Financials
Cash vs Debt
Where FRNM stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, FRNM finished 34.94% above its 150-day moving average ($11.82) and 33.14% above its 200-day moving average ($11.98). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is FRNM overbought or oversold?
At the September 3, 2026 close, FRNM's RSI(14) was 93.1, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Freenome, Inc. carries $311.5M in total debt against $102.0M in cash reserves — debt is roughly 3.1x the cash position. Managing this leverage effectively will be important for long-term financial stability. Revenue has grown from $2.9M (2024) to $30.4M (2025), reflecting a 955% increase over the period.
With a beta below 0.7, Freenome, Inc. typically sees smaller price swings than the overall market, offering a degree of stability during turbulent periods. No single metric tells the full story. Reviewing FRNM's risk profile alongside its fundamentals and technical indicators provides a more complete picture.